معرفی
Univ-Prof. Dr. med. Malek Bajbouj serves as Director of the Institute for Affective Neuroscience and Emotion Modulation at Charité – University Medicine Berlin's Campus Benjamin Franklin (CBF), operating within the Department of Neurology, Neurosurgery and Psychiatry (CC 15). His position integrates clinical leadership with translational neuroscience research focused on severe mental illnesses.
Dr. Bajbouj's research program centers on affective neuroscience and emotion dysregulation mechanisms in psychiatric disorders, particularly schizophrenia spectrum conditions and depression. He pioneers multimodal intervention approaches combining neuromodulation (tDCS), oxytocin augmentation, mindfulness therapies, and digital health tools. His work emphasizes translational biomarker development using neuroimaging, machine learning, and physiological stress parameter analysis to personalize treatment for treatment-resistant populations.
Analysis of his 2023-2025 publications reveals three dominant research trajectories: (1) novel treatment combinations for negative symptoms in schizophrenia (oxytocin + mindfulness, yoga therapy); (2) real-world implementation of neuromodulation (at-home tDCS protocols, technical efficacy monitoring); and (3) global mental health responses to crises (pandemic impacts on vulnerable groups, culturally adapted refugee interventions). His methodology consistently employs rigorous randomized controlled trials with embedded biomarker studies.
As director of his eponymous institute, Dr. Bajbouj leads a multidisciplinary team conducting neuroimaging studies, clinical trials, and international collaborations focused on emotion modulation pathways. The institute coordinates research across CC 15's clinical infrastructure at CBF Building V, with particular emphasis on bridging laboratory neuroscience with clinical psychiatry through the DepressionDC and OXYMIND trial frameworks.
